Ideas For Now-

stonedinvestor said:
Good Sunday To All. I have been thinking for a while now how the hell I get out of this thread-- or has life just overwhelmed everything and the thread must continue. As I see it a few things are happening The Election, The Correction, The Rotation and the Connection.

Everyone is calling for volatility into the election. I hate when they say that on TV what is volatility but down? They never say volatility when we are already down do you catch that? It's always when we are riding high they say volatility which is wordspeak for Down. Just say it.
So one idea is to ride this thread right through the election and that would be a good point to sign off.

But is this thread a way of life? I'm really surprised this has gone on for 159 pages! It started so innocently with 4 stocks. I have to look myself in the mirror and ask am I trading too much? I don't think so I use the word rotation it sounds a lot better than addicted to all of this.

And we have this medical angle the Covid response which really puts the focus on Med Tech, a good area for me. So I'm conflicted. I notice that while Van's "Likes" have held rock steady at a very high level, My " Likes " have actually more than doubled. Just like my stocks.~si
More...
35,000 views stoney fwiw. You're a rock-star. Tesla 2020 is a distant second and its almost 4 months older. GBA must press on.
 
How James Bond Got a Lot Of People Fired. Folks in order to get through these times we have to think smart. Someone should of payed off MGM to release James Bond on Time. It's VERY important. A whole industry basically rests on it... now with a delay bad stuff is going to happen all over to a movie theater near you. It is also psychologically damaging.

Already the white color wave of layoffs has begun. The next jobs report is going to be very bad. The recovery has stalled and we really need James Bond.

Cineworld to close Regal, UK theaters after 007 delay
Oct. 4, 2020 5:47 AM ET|About:ADR (CNWGY)|

Just a couple of days after another major movie release delay, Cineworld (OTC:CNWGY) is set to close all its 543 Regal Cinema venues and its 128 theaters in the U.K. and Ireland.

On Friday, MGM (OTC:MGMB) and Universal(NASDAQ:CMCSA) pushed the release of the latest James Bond title No Time to Die, Daniel Craig's last outing in the role, to -->April 2021.

Ironically the Covid recovery-- back to normal date- also--> 2021.

The closures, with no timeline for reopening, will affect 5,500 jobs in the U.K.

Can Wonder Women save the market?- No. Not like James Bond. James Bond is a familiar event that will make everyone all ages feel better. Wonder Women will make a few teen age girls feel better. Dune is just weird.

Delayed titles Wonder Woman 1984 and Dune(NYSE:T) are set for December release, so far. The top film on release calendars pre-December is now Pixar(NYSE:DIS) release Soul, set for Nov. 20.<----

Right around the election! " Soul " Ironic-- just what the Republican party lacks. The only better title would of been " Blue Wave. "

 
vanzandt said:
Regeneron is gonna be a good one to play Monday that's for sure.
More...

I'm not so sure.... I don't see a whole lot of $'s coming from this REGN product. I mean we can't all have twelve guys in white coats hold our hand and take Marine 1 to the hospital the moment we start feeling run down can we?

Regeneron antibody cocktail results positive for vaccines, says Jefferies 08:00 GILD, REGN Jefferies analyst Michael Yee said Regeneron's (REGN) COVID-19 antibody cocktail study results "looks great for a particular subset of patients," namely those who are infected but not hospitalized, -->which differs from Gilead's (GILD) studies with Remdesivir, which were done on much sicker, hospitalized patients. While unclear, it is possible that the Regeneron cocktail could work in a hospital setting where patients are already severely ill and have a high viral load, but he expects that it would be used in combination with Remdesivir, which has proven a benefit in such patients already, Yee said. The data from Regeneron are also an "incremental positive" for vaccines as they suggest that having existing antibodies, or giving antibodies as a drug, "shifts" the curve and helps people resolve faster, according to Yee. He maintains a Buy rating and $78 price target on Gilead shares.

I don't love GILD either it has been such a troubled stock over the years/

Piper Sandler 'incrementally more positive' on Regeneron after COVID cocktail 20:46 REGN Piper Sandler analyst Christopher Raymond keeps his Overweight rating and $675 price target on Regeneron after the company provided its "long awaited" initial data on its COVID-19 therapeutic antibody cocktail. The analyst notes that the early critiques "miss the forest through the trees", and that the cocktail represents a "clear reduction of viral load and time to symptom alleviation". Its "pristine" safety profile should also give the FDA enough evidence to issue an Emergency Use Authorization, Raymond tells investors in a research note.

$565 now ... so expensive but I guess... It's not going to go down that's for sure! .. My guess is though it stalls out at like $620.

Hummm I wonder if any small biotechs in Israel have been working on plasma-derived hyperimmune immunoglobulin -? Getting no respect. This news on Sept 8th got no reaction.

Kamada announces intial interim rsults from Phase 1/2 trial of IgG product 09/08 KMDA Kamada announced the completion of enrollment and initial interim results from its ongoing Phase 1/2 open-label, single-arm, multi-center clinical trial in Israel of the Company's anti-SARS-CoV-2 plasma-derived hyperimmune immunoglobulin product as a potential treatment for coronavirus disease. The trial is designed to assess the safety, pharmacokinetics, and pharmacodynamics of Kamada's plasma-derived IgG product in hospitalized, non-ventilated COVID-19 patients with pneumonia. A total of 12 eligible patients were enrolled in the trial and received the Company's product at a single dose of 4 grams <- OK TIME OUT I AM NOT A Dr BUT THAT SOUNDS LIKE A PILL.... Better THAN REGN which is through the veins...

IgG within five to 10 days of initial symptoms. Patient follow-up will occur for 84 days. To date, five of the 12 patients have completed 21-day post-treatment follow-up, two patients have completed 14-day post-treatment follow-up and the additional five patients have completed 7-day post-treatment follow-up. Symptoms improvement was observed in 11 of the 12 patients within 24 to 48 hours from treatment. <--- HEY!!!! All 11 patients were subsequently discharged from the hospital within a median hospital stay of 4.5 days from treatment.

Hello? This should of gotten a huge response but the market is just so shell shocked over all of this-- Now with the heightened and positive view of these cocktails all we need is for Robin Hood to put his damn green tights on and realize KAMADA is the way to play this!

The medical condition of one patient, who completed the 14-day post-treatment follow-up, deteriorated and this individual is currently on mechanical ventilation. Well you can't win them all.

One patient had a serious adverse event four days after treatment, which was categorized by the investigator as unrelated to the Company's IgG product, that the patient received in the trial. The Phase 1/2 trial in Israel is being conducted as part of Kamada's global collaboration with Kedrion Biopharma, established in April 2020, for the development, manufacturing, and distribution of a plasma-derived IgG product as a potential treatment for COVID-19. With Kedrion's support, Kamada submitted a pre-Investigational New Drug information package to the U.S. FDA, with its proposed U.S clinical development plan, FDA's response is expected next month.

OK Question time Next Month... How Do You Say No To These guys when what's happened has happened to REGN-?

THE PLAY IS KMDA @$8.00!!!!!! THIS WILL BE $12+ SOON. ~stoney
 
stonedinvestor said:
VAN watch HGEN.

This might be the better $1 move....

It's only one patient so you know this improvement could be attributed to anything...
BUT->
Humanigen Announces COVID-19 Case Report Demonstrating Rapid Resolution and Discharge after Single IND Emergency Use Authorization of Lenzilumab(TM)

ACCESSWIRE•October 2, 2020
  • Case report demonstrated rapid resolution of hypoxemia and mobility and potential benefit of lenzilumab beyond the initial acute hyper-inflammatory window
  • After 13 weeks of hospitalization, administration of lenzilumab resulted in rapid improvement in oxygenation and subsequent discharge
BURLINGAME, CA / ACCESSWIRE / October 2, 2020 / Humanigen, Inc.,(NASDAQ:HGEN)("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' today announced that a patient case report on the use of lenzilumab™ in critical COVID-19 was published online at OSF Preprints. The case report, titled "COVID-19 associated chronic ARDS successfully treated with lenzilumab" is available at:https://osf.io/xusr9/.

The published case describes a 77-year-old Caucasian male patient with a past medical history of type II diabetes, coronary artery disease with coronary artery bypass graft, systolic heart failure, severe chronic obstructive pulmonary disease (COPD) with emphysema and obstructive sleep apnea. The patient tested positive for SARS-CoV-2 and was admitted to the ICU in March 2020 for COVID-19 and put on respiratory isolation. MARCH!!!

The patient was treated with steroids, broad spectrum antibiotics for community acquired pneumonia and bronchodilators for possible COPD exacerbation and hydroxychloroquine with zinc. The patient continued to deteriorate for the next 12 weeks with an increase in oxygen demand from continuous low-flow oxygen to high-flow and eventually intermittent bilevel positive airway pressure (BIPAP) and developed acute respiratory distress syndrome (ARDS) during that time.<-- serious

At week 13 of hospitalization and multiple unsuccessful attempts at oxygen weaning, an emergency single use IND for lenzilumab, Humanigen's Humaneered®anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody drug candidate, was approved by the FDA and administered to the patient. Seven days following the administration of lenzilumab, the patient's oxygen decreased from high-flow to low-flow nasal cannula and the patient was able to walk outside of his hospital room with physical therapy. Sixteen days post-treatment with lenzilumab, the patient was discharged from the hospital on home oxygen.

16 days later he walks out!

Lenzilumab is being evaluated in an ongoing Phase 3 trial....
More...


HGEN
4.22K followersHumanigen, Inc.
12.30
2.45 (+24.87%)<-------------
10:19 AM 10/05/20
 
I am in a bad place. First off two stocks I sold have started doing well now that people are looking for value. Trane and Fortive. Very angry. Next a bio I have scouted for a very long time MYOK got bought a staggering blow. And then I open my screen and the bio we talked about last week with the Martin Schinkle connection well that explodes. --> ~si
 
Sometimes in investing you feel like the guy walking with a hand grenade in his pocket. Fully activated although he is unawares... walking proudly into the fog...
 
You must log in or register to reply here.
Back
Top